Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences